These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23660778)

  • 1. Modeling of PET data in CNS drug discovery and development.
    Varnäs K; Varrone A; Farde L
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging in Central Nervous System Drug Discovery.
    Gunn RN; Rabiner EA
    Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.
    Schou M; Varnäs K; Lundquist S; Nakao R; Amini N; Takano A; Finnema SJ; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2015 Mar; 18(10):pyv036. PubMed ID: 25813017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy.
    Naganawa M; Gallezot JD; Rossano S; Carson RE
    Bull Math Biol; 2019 Sep; 81(9):3508-3541. PubMed ID: 29230702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro, in vivo and in silico models of drug distribution into the brain.
    Summerfield SG; Dong KC
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):301-14. PubMed ID: 23404394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Practical
    Handa K; Fujita D; Hirano M; Yoshimura S; Kageyama M; Iijima T
    Mol Pharm; 2024 Oct; 21(10):5182-5191. PubMed ID: 39324316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral uptake of drugs in humans.
    Upton RN
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):695-701. PubMed ID: 17600543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of PET scan timings for receptor occupancy studies of CNS drugs: a simple fixed-time design performed as well as scattered time point designs.
    Lee J; Jeon S; Hong T; Han S; Yim DS
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1333-9. PubMed ID: 26350521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
    Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
    Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
    Langer O
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).
    Huang Y; Hwang DR; Bae SA; Sudo Y; Guo N; Zhu Z; Narendran R; Laruelle M
    Nucl Med Biol; 2004 Jul; 31(5):543-56. PubMed ID: 15219271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomographic imaging in drug discovery.
    Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
    Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of CNS drugs with PET].
    Takano A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational PET imaging research.
    Hargreaves RJ; Rabiner EA
    Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demystifying brain penetration in central nervous system drug discovery. Miniperspective.
    Di L; Rong H; Feng B
    J Med Chem; 2013 Jan; 56(1):2-12. PubMed ID: 23075026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
    Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain.
    Finnema SJ; Stepanov V; Ettrup A; Nakao R; Amini N; Svedberg M; Lehmann C; Hansen M; Knudsen GM; Halldin C
    Neuroimage; 2014 Jan; 84():342-53. PubMed ID: 23994452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.
    de Lange ECM; van den Brink W; Yamamoto Y; de Witte WEA; Wong YC
    Expert Opin Drug Discov; 2017 Dec; 12(12):1207-1218. PubMed ID: 28933618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences.
    Syvänen S; Blomquist G; Appel L; Hammarlund-Udenaes M; Långström B; Bergström M
    Eur J Clin Pharmacol; 2006 Oct; 62(10):839-48. PubMed ID: 16896783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.